VIENNA – In addition to the internet and the graphical user interface, a cure for the common cold could soon feature among the many technological achievements supported by the Defense Advanced Research Projects Agency (DARPA). Early last year, London-based startup Virion Biotherapeutics Ltd. received £3 million (US$4 million) in funding from the U.S. Department of Defense's research funding arm to develop a broad-spectrum antiviral technology, based on defective interfering viruses, which it calls Therapeutic Infectious Particles (TIPs). The company has maintained a relatively low profile since its inception in 2017, but it has recently completed a reboot, with a new name and a new leadership team in place, and it set out plans to move to the clinic in the next couple of years during the BIO Europe meeting.